Kratom Alkaloids: A Blueprint?
ACS Chemical Neuroscience · 2023
DOI: 10.1021/acschemneuro.2c00704 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2023. Verfasst von Kirsten Elin Smith und 3 weiteren Autor:innen. Beteiligte Einrichtung: Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, 251 Bayview Boulevard, Baltimore…. Hauptthemen laut MEDLINE: Secologanin Tryptamine Alkaloids, Substance-Related Disorders, Mitragyna. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, Intramural NIH HHS, National Institute on Drug Abuse.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, 251 Bayview Boulevard, Baltimore, Maryland 21224, United States.
- Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida 32610, United States.
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida 32610, United States.
ORCID-Profile: Abhisheak Sharma, Christopher R McCurdy
Förderung
- NIDA NIH HHS
- Intramural NIH HHS
- National Institute on Drug Abuse
Zitieren
APA
Smith, K. E., Sharma, A., Grundmann, O., & McCurdy, C. R. (2023). Kratom Alkaloids: A Blueprint?. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.2c00704
Vancouver
Smith KE, Sharma A, Grundmann O, McCurdy CR. Kratom Alkaloids: A Blueprint?. ACS Chemical Neuroscience. 2023. doi:10.1021/acschemneuro.2c00704
BibTeX
@article{Smith2023,
author = {Smith, Kirsten Elin and Sharma, Abhisheak and Grundmann, Oliver and McCurdy, Christopher R},
title = {Kratom Alkaloids: A Blueprint?},
journal = {ACS Chemical Neuroscience},
year = {2023},
doi = {10.1021/acschemneuro.2c00704}
}
EUVIMED